Hologic gets win in ongoing dispute with SenoRx

The U.S. Court of Appeals for the Federal Circuit has reversed a ruling that invalidated Hologic's patent claims against a SenoRx device used for the treatment of breast cancers. The ruling comes more than two years after a California court decided in SenoRx's favor. 

Citing an incorrect claim construction, the appeals court reversed the lower court's ruling and remanded for further proceedings. "We are extremely pleased that the Court adopted our proffered claim construction and reinstated the validity of the claims of this pioneering patent in the area of breast brachytherapy," said Mark Casey, senior VP and general counsel.

Shares of Hologic were recently up 3.7 percent to $20.57, the Wall Street Journal reports. The stock has risen 22 percent in the past year.

SenoRx was acquired by CR Bard for $213 million last July, Reuters notes.

- see the Hologic release
- get more from Reuters
- check out the WSJ report

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.